Beth Apsel

1.8k total citations · 1 hit paper
7 papers, 1.5k citations indexed

About

Beth Apsel is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Beth Apsel has authored 7 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Pharmacology and 2 papers in Organic Chemistry. Recurrent topics in Beth Apsel's work include PI3K/AKT/mTOR signaling in cancer (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Inflammatory mediators and NSAID effects (2 papers). Beth Apsel is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Inflammatory mediators and NSAID effects (2 papers). Beth Apsel collaborates with scholars based in United States, Switzerland and United Kingdom. Beth Apsel's co-authors include Zachary A. Knight, Kevan M. Shokat, Davide Ruggero, Morris E. Feldman, Robbie Loewith, Roger Williams, Tamim Nazif, Randy Hoffman, Jimmy A. Blair and Beatriz González and has published in prestigious journals such as The Journal of Immunology, Cancer Cell and PLoS Biology.

In The Last Decade

Beth Apsel

7 papers receiving 1.5k citations

Hit Papers

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant... 2009 2026 2014 2020 2009 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth Apsel United States 7 1.1k 205 181 161 158 7 1.5k
Yukimasa Shiotsu Japan 22 1.1k 1.0× 104 0.5× 305 1.7× 235 1.5× 88 0.6× 47 1.8k
Eric G. Bremer United States 16 814 0.7× 227 1.1× 172 1.0× 394 2.4× 153 1.0× 19 1.5k
X. Wei Meng United States 21 901 0.8× 166 0.8× 335 1.9× 246 1.5× 62 0.4× 31 1.4k
E. Ahn United States 22 869 0.8× 111 0.5× 210 1.2× 168 1.0× 59 0.4× 55 1.4k
Lang Ngo United States 17 2.2k 2.0× 166 0.8× 705 3.9× 127 0.8× 179 1.1× 19 2.5k
Sha Jin United States 13 1.6k 1.4× 126 0.6× 620 3.4× 252 1.6× 155 1.0× 30 2.2k
Masaki Ri Japan 24 1000 0.9× 249 1.2× 576 3.2× 446 2.8× 110 0.7× 117 1.9k
Martin Schröder Germany 21 678 0.6× 65 0.3× 284 1.6× 134 0.8× 142 0.9× 45 1.3k
Mari Nishino United States 8 1.3k 1.2× 285 1.4× 309 1.7× 228 1.4× 42 0.3× 12 1.7k
Roberta Bortul Italy 26 1.7k 1.5× 94 0.5× 349 1.9× 238 1.5× 50 0.3× 60 2.2k

Countries citing papers authored by Beth Apsel

Since Specialization
Citations

This map shows the geographic impact of Beth Apsel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Apsel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Apsel more than expected).

Fields of papers citing papers by Beth Apsel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Apsel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Apsel. The network helps show where Beth Apsel may publish in the future.

Co-authorship network of co-authors of Beth Apsel

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Apsel. A scholar is included among the top collaborators of Beth Apsel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Apsel. Beth Apsel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Feldman, Morris E., Beth Apsel, Robbie Loewith, et al.. (2009). Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2. PLoS Biology. 7(2). e1000038–e1000038. 889 indexed citations breakdown →
2.
Zunder, Eli R., Zachary A. Knight, Benjamin T. Houseman, Beth Apsel, & Kevan M. Shokat. (2008). Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α. Cancer Cell. 14(2). 180–192. 76 indexed citations
3.
Apsel, Beth, Jimmy A. Blair, Beatriz González, et al.. (2008). Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology. 4(11). 691–699. 339 indexed citations
4.
Mackey, Zachary B., Arthur M. Baca, Jeremy P. Mallari, et al.. (2006). Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei. Chemical Biology & Drug Design. 67(5). 355–363. 91 indexed citations
5.
Pillinger, Michael H., Beth Apsel, Sonia Tolani, et al.. (2004). Regulation of metalloproteinases and NF‐κB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: contrasting effects of nabumetone and 6MNA. British Journal of Pharmacology. 142(6). 973–982. 16 indexed citations
6.
Pillinger, Michael H., Perry Rosenthal, Sonia Tolani, et al.. (2003). Cyclooxygenase-2-Derived E Prostaglandins Down-Regulate Matrix Metalloproteinase-1 Expression in Fibroblast-Like Synoviocytes via Inhibition of Extracellular Signal-Regulated Kinase Activation. The Journal of Immunology. 171(11). 6080–6089. 71 indexed citations
7.
Apsel, Beth, et al.. (2003). General entries to C-aryl glycosides. Formal synthesis of galtamycinone. Tetrahedron Letters. 44(5). 1075–1077. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026